AOPPs and the progression of kidney disease

Kidney International Supplements

Volumn 4, Issue 1, 2014, Pages 102-106

  Cao, Wei ^a   Hou, Fan Fan ^a   Nie, Jing ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AOPPs; CD36; NAD(P)H oxidase; oxidative stress; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; CANDESARTAN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN D;

APOPTOSIS; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DISEASE COURSE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; MESANGIUM CELL; OXIDATIVE STRESS; PATHOGENESIS; PERITONEAL DIALYSIS; PODOCYTE; REVIEW; VASCULITIS;

EID: 84908501565     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2014.19     Document Type: Short Survey

References (29)

1. Tucker PS, Dalbo VJ, Han T et al. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers 2013; 18: 103-115.
2. Granata S, Zaza G, Simone S et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009; 10: 388.
3. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
4. Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potenti@@al uremic toxins? Kidney Int Suppl 2003; 84: S11-S14.
5. Capeillere-Blandin C, Gausson V, Descamps-Latscha B et al. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta 2004; 1689: 91-102.
6. Witko-Sarsat V, Friedlander M, Nguyen Khoa T et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
7. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-748.
8. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11: 2395-2403.
9. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int 2004; 66: 1606-1612.
10. Camilla R, Suzuki H, Dapra V et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 2011; 6: 1903-1911.
11. Cao W, Xu J, Zhou ZM et al. Advanced oxidation protein products activate intrarenal renin-angiotensin system via a CD36-mediated, redoxdependent pathway. Antioxid Redox Signal 2013; 18: 19-35.
12. Lentini P, de Cal M, Cruz D et al. The role of advanced oxidation protein products in intensive care unit patients with acute kidney injury. J Crit Care 2010; 25: 605-609.
13. Zhou LL, Hou FF, Wang GB et al. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int 2009; 76: 1148-1160.
14. Guo ZJ, Niu HX, Hou FF et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008; 10: 1699-1712.
15. Wei XF, Zhou QG, Hou FF et al. Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase. Am J Physiol Renal Physiol 2009; 296: F427-F437.
16. Li HY, Hou FF, Zhang X et al. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol 2007; 18: 528-538.
17. Shi XY, Hou FF, Niu HX et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 2008; 149: 1829-1839.
18. Coppo R, Camilla R, Alfarano A et al. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int 2009; 75: 536-541.
19. Witko-Sarsat V, Gausson V, Nguyen AT et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82-91.
20. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45: 39-47.
21. Zhou Q, Wu S, Jiang J et al. Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients. Nephrology (Carlton) 2012; 17: 642-649.
22. Kocak H, Gumuslu S, Sahin E et al. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology (Carlton) 2009; 14: 273-280.
23. Marsche G, Frank S, Hrzenjak A et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 2009; 104: 750-757.
24. Liu SX, Hou FF, Guo ZJ et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1156-1162.
25. Marsche G, Semlitsch M, Hammer A et al. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. FASEB J 2007; 21: 1145-1152.
26. Iwao Y, Nakajou K, Nagai R et al. CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products. Am J Physiol Renal Physiol 2008; 295: F1871-F1880.
27. Zhou LL, Cao W, Xie C et al. The receptor of advanced glycation end products plays a central role in advanced oxidation protein productsinduced podocyte apoptosis. Kidney Int 2012; 82: 759-770.
28. Furuya R, Odamaki M, Kumagai H et al. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif 2006; 24: 445-450.
29. Gradinaru D, Borsa C, Ionescu C et al. Vitamin D status and oxidative stress markers in the elderly with impaired fasting glucose and type 2 diabetes mellitus. Aging Clin Exp Res 2012; 24: 595-602.